Should	O
the	O
cost	O
of	O
medicines	O
be	O
reduced	O
?	O

At	O
present	O
,	O
a	O
large	O
number	O
of	O
patients	O
in	O
poor	O
countries	O
are	O
suffering	O
from	O
deaths	O
caused	O
by	O
lack	O
of	O
medication	O
rather	O
than	O
dangerous	O
diseases	O
.	O

It	O
is	O
suggested	O
that	O
companies	O
in	O
developed	O
countries	O
ought	O
to	O
reduce	O
their	O
price	O
of	O
medicines	O
to	O
avoid	O
such	O
unnecessary	O
deaths	O
.	O

Admittedly	O
,	O
more	B-Premise-supports-4
lives	I-Premise-supports-4
will	I-Premise-supports-4
be	I-Premise-supports-4
saved	I-Premise-supports-4
by	I-Premise-supports-4
the	I-Premise-supports-4
use	I-Premise-supports-4
of	I-Premise-supports-4
effective	I-Premise-supports-4
medicines	I-Premise-supports-4
.	O

The	B-Premise-supports-3
medical	I-Premise-supports-3
industry	I-Premise-supports-3
in	I-Premise-supports-3
developing	I-Premise-supports-3
countries	I-Premise-supports-3
is	I-Premise-supports-3
incapable	I-Premise-supports-3
of	I-Premise-supports-3
producing	I-Premise-supports-3
high-quality	I-Premise-supports-3
drugs	I-Premise-supports-3
.	O

With	B-Premise-supports-2
advanced	I-Premise-supports-2
technology	I-Premise-supports-2
,	I-Premise-supports-2
the	I-Premise-supports-2
developed	I-Premise-supports-2
world	I-Premise-supports-2
has	I-Premise-supports-2
achieved	I-Premise-supports-2
remarkable	I-Premise-supports-2
breakthroughs	I-Premise-supports-2
in	I-Premise-supports-2
making	I-Premise-supports-2
medicines	I-Premise-supports-2
,	I-Premise-supports-2
which	I-Premise-supports-2
can	I-Premise-supports-2
cure	I-Premise-supports-2
a	I-Premise-supports-2
variety	I-Premise-supports-2
of	I-Premise-supports-2
serious	I-Premise-supports-2
illnesses	I-Premise-supports-2
.	O

If	B-Premise-supports-1
people	I-Premise-supports-1
in	I-Premise-supports-1
poorer	I-Premise-supports-1
countries	I-Premise-supports-1
gain	I-Premise-supports-1
access	I-Premise-supports-1
to	I-Premise-supports-1
these	I-Premise-supports-1
drugs	I-Premise-supports-1
,	I-Premise-supports-1
their	I-Premise-supports-1
health	I-Premise-supports-1
situations	I-Premise-supports-1
may	I-Premise-supports-1
be	I-Premise-supports-1
better	I-Premise-supports-1
.	O

The	B-Claim-attacks-9
reduction	I-Claim-attacks-9
in	I-Claim-attacks-9
cost	I-Claim-attacks-9
of	I-Claim-attacks-9
medicines	I-Claim-attacks-9
therefore	I-Claim-attacks-9
shows	I-Claim-attacks-9
the	I-Claim-attacks-9
sign	I-Claim-attacks-9
of	I-Claim-attacks-9
humanity	I-Claim-attacks-9
.	O

However	O
,	O
the	B-Claim-supports-8
current	I-Claim-supports-8
cost	I-Claim-supports-8
of	I-Claim-supports-8
medicines	I-Claim-supports-8
is	I-Claim-supports-8
,	I-Claim-supports-8
in	I-Claim-supports-8
fact	I-Claim-supports-8
,	I-Claim-supports-8
reasonable	I-Claim-supports-8
and	I-Claim-supports-8
based	I-Claim-supports-8
on	I-Claim-supports-8
the	I-Claim-supports-8
medicines	I-Claim-supports-8
'	I-Claim-supports-8
effectiveness	I-Claim-supports-8
.	O

Apparently	O
,	O
the	B-Premise-supports--1
process	I-Premise-supports--1
of	I-Premise-supports--1
researching	I-Premise-supports--1
,	I-Premise-supports--1
testing	I-Premise-supports--1
and	I-Premise-supports--1
producing	I-Premise-supports--1
drugs	I-Premise-supports--1
in	I-Premise-supports--1
masses	I-Premise-supports--1
costs	I-Premise-supports--1
a	I-Premise-supports--1
substantial	I-Premise-supports--1
amount	I-Premise-supports--1
of	I-Premise-supports--1
money	I-Premise-supports--1
.	O

Moreover	O
,	O
these	B-Premise-supports-2
products	I-Premise-supports-2
prove	I-Premise-supports-2
to	I-Premise-supports-2
ensure	I-Premise-supports-2
human	I-Premise-supports-2
health	I-Premise-supports-2
completely	I-Premise-supports-2
.	O

Suppose	B-Premise-supports-1
companies	I-Premise-supports-1
were	I-Premise-supports-1
forced	I-Premise-supports-1
to	I-Premise-supports-1
reduce	I-Premise-supports-1
the	I-Premise-supports-1
cost	I-Premise-supports-1
of	I-Premise-supports-1
drugs	I-Premise-supports-1
,	I-Premise-supports-1
they	I-Premise-supports-1
would	I-Premise-supports-1
make	I-Premise-supports-1
no	I-Premise-supports-1
profit	I-Premise-supports-1
,	I-Premise-supports-1
even	I-Premise-supports-1
running	I-Premise-supports-1
up	I-Premise-supports-1
debt	I-Premise-supports-1
because	I-Premise-supports-1
of	I-Premise-supports-1
production	I-Premise-supports-1
expenditure	I-Premise-supports-1
.	O

Therefore	O
,	O
the	B-Claim-supports-4
measure	I-Claim-supports-4
can	I-Claim-supports-4
not	I-Claim-supports-4
be	I-Claim-supports-4
adopted	I-Claim-supports-4
,	I-Claim-supports-4
otherwise	I-Claim-supports-4
those	I-Claim-supports-4
companies	I-Claim-supports-4
will	I-Claim-supports-4
go	I-Claim-supports-4
into	I-Claim-supports-4
liquidation	I-Claim-supports-4
.	O

In	O
short	O
,	O
this	O
is	O
not	O
a	O
long-term	O
solution	O
.	O

Fortunately	O
,	O
there	B-Claim-supports-3
are	I-Claim-supports-3
other	I-Claim-supports-3
measures	I-Claim-supports-3
to	I-Claim-supports-3
improve	I-Claim-supports-3
the	I-Claim-supports-3
situation	I-Claim-supports-3
.	O

It	B-Premise-supports--1
is	I-Premise-supports--1
advisable	I-Premise-supports--1
for	I-Premise-supports--1
the	I-Premise-supports--1
government	I-Premise-supports--1
to	I-Premise-supports--1
encourage	I-Premise-supports--1
medical	I-Premise-supports--1
production	I-Premise-supports--1
by	I-Premise-supports--1
supplying	I-Premise-supports--1
land	I-Premise-supports--1
for	I-Premise-supports--1
building	I-Premise-supports--1
factories	I-Premise-supports--1
and	I-Premise-supports--1
reducing	I-Premise-supports--1
part	I-Premise-supports--1
of	I-Premise-supports--1
the	I-Premise-supports--1
taxes	I-Premise-supports--1
.	O

Additionally	O
,	O
charitable	B-Premise-supports--2
organizations	I-Premise-supports--2
can	I-Premise-supports--2
buy	I-Premise-supports--2
medicines	I-Premise-supports--2
from	I-Premise-supports--2
developed	I-Premise-supports--2
countries	I-Premise-supports--2
and	I-Premise-supports--2
distribute	I-Premise-supports--2
to	I-Premise-supports--2
the	I-Premise-supports--2
undeveloped	I-Premise-supports--2
world	I-Premise-supports--2
for	I-Premise-supports--2
free	I-Premise-supports--2
.	O

In	O
conclusion	O
,	O
I	B-MajorClaim
disagree	I-MajorClaim
with	I-MajorClaim
reducing	I-MajorClaim
the	I-MajorClaim
cost	I-MajorClaim
of	I-MajorClaim
medicines	I-MajorClaim
,	I-MajorClaim
which	I-MajorClaim
may	I-MajorClaim
exacerbate	I-MajorClaim
their	I-MajorClaim
qualities	I-MajorClaim
.	O

Instead	O
,	O
the	O
government	O
and	O
medical	O
foundations	O
should	O
be	O
responsible	O
for	O
the	O
distribution	O
of	O
drugs	O
to	O
the	O
undeveloped	O
world	O
at	O
a	O
more	O
reasonable	O
price	O
.	O

